Predict your next investment

Corporation

See what CB Insights has to offer

About MDS Analytical

MDS Analytical is a drug discovery and life sciences company.

MDS Analytical Headquarter Location

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest MDS Analytical News

Email to a friend Follow us on Twitter Follow us on Facebook Follow us on LinkedIn MDS Analytical buys Blueshift Biotechnologies

Jan 14, 2019

By Dr Matt Wilkinson Molecular Devices last year by snapping up high content screening (HCS) experts Blueshift for $15m (€9.45m). The acquisition bolsters MDS's cellular analysis offering, enablingthe firm to offer its pharmaceutical and biopharmaceuticalcustomers a cost-effective way of adding HCS into their drugdiscovery programmes.HCS is a technique used during the drug discovery process thatprovides information about the effects of drug candidates onvarious cellular processes occurring within living cells.Most plate readers used for HCS only measure the average signal fora whole microtiter well or a small area of the well, whilemicroscopes image only the field of view allowed by the objectivelens.In contrast, Blueshift's flagship IsoCyte instrument enablesresearchers to quickly image the entire cell population held in amicrotiter plate well in four colours at the same time. "This acquisition fills a gap in our current product portfolio,allowing us to offer our pharmaceutical research customers fast andsimple cellular analysis with a line of instrumentation that imagesthe whole well at true high throughput screening rates,"​ saidAndy Boorn, president of MDS Analytical Technologies.​"There are currently fourteen IsoCyteinstruments installed at academic, biotech and pharmaceuticalcompanies in North America. With our extensive global sales force,we have the ability to bring this novel product to a wider globalmarket." ​The instrument rapidly scans a laser across the bottom of amicroplate or slide before the fluorescence emission is collectedwith an optical head and measured using photomultiplier tubes. Theemission pattern is mapped in 2-dimensions through time-basedcorrelation to allow the construction of a fluorescenceimage.The system's unique optics enable it to generate anisotropymeasurements about the degree of polarized emission from an excitedmolecule in a range of environments from microarrays, beads, cellsand homogenous solutions.This can be particularly useful for conducting FRET (fluorescenceresonance energy transfer) measurements as faster measurements canbe made with higher signal to noise ratios.Fluorescent proteins typically emit highly polarised light whenexcited directly by a laser, but when FRET occurs this non-opticalresonance depolarizes the emissions. In addition to measuring theemission ratio of the donor and acceptor, the drop in anisotropycan be used to characterise protein-protein interactions in livingcells on a cell by cell basis over time. "We are very excited about this opportunity for BlueshiftBiotechnologies to merge into a world-class company like MDSAnalytical Technologies,"​ said Evan Cromwell, president ofBlueshift Biotechnologies.​"The breadth and strength of its sales andmarketing efforts mean that we will be able to increase awarenessof this unique high-throughput imaging tool in newmarkets." ​ Copyright - Unless otherwise stated all contents of this web site are © 2020 - William Reed Business Media Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions

MDS Analytical Acquisitions

1 Acquisition

MDS Analytical acquired 1 company. Their latest acquisition was Blueshift Biotechnologies on July 05, 2008.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/5/2008

$991

Acquired

1

Date

7/5/2008

Investment Stage

Companies

Valuation

$991

Total Funding

Note

Acquired

Sources

1

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.